Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: A retrospective analysis

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1859-1864

  Barnes, J A ^a,b   LaCasce, A S ^b,c   Feng, Y ^c   Toomey, C E ^a   Neuberg, D ^c,d   Michaelson, J S ^b,e   Hochberg, E P ^a,b   Abramson, J S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AIDS; Burkitt's lymphoma; HIV; Magrath regimen; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; BURKITT LYMPHOMA; CANCER RELAPSE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK REDUCTION; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 79961007328     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq677     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
2. Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
3. Mead GM, Sydes MR, Walewski J et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264-1274.
4. Lacasce A, Howard O, Lib S et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45: 761-767.
5. Mead GM, Barrans SL, Qian W et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248-2260.
6. Oriol A, Ribera JM, Bergua J et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008; 113: 117-125.
7. Wang ES, Straus DJ, Teruya-Feldstein J et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98: 1196-1205.
8. Cortes J, Thomas D, Rios A et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-1499.
9. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
10. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
11. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
12. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
13. Pfreundschuh M, Trümper L, Österborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
14. Thomas DA, Faderl S, O'Brien S et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-1580.
15. Dunleavy K, Pittaluga S, Janik J et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome. ASH Annual Meeting Abstracts 2006; 108: 2736.
16. Fayad L, Thomas D, Romaguera J. Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007; 8: S57-S62.
17. Dave SS, Fu K, Wright GW et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442.
18. Swerdlow S, Campo E, Harris NLet al. (eds). WHO Classification of Tumours of Haematopoetic and Lymphoid Tissue. Lyon, France: IARC 2008.
19. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.